​

Fennec Pharmaceuticals (FENC) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

FENC Stock Forecast

Fennec Pharmaceuticals stock forecast is as follows: an average price target of $15.75 (represents a 162.94% upside from FENC’s last price of $5.99) and a rating consensus of 'Buy', based on 12 wall street analysts offering a 1-year stock forecast.

FENC Price Target

The average price target for Fennec Pharmaceuticals (FENC) is $15.75 based on 1-year price targets from 12 Wall Street analysts in the past 3 months, with a price target range of $19.00 to $12.00. This represents a potential 162.94% upside from FENC's last price of $5.99.

FENC Analyst Ratings

Buy

According to 12 Wall Street analysts, Fennec Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for FENC stock is 0 'Strong Buy' (0.00%), 11 'Buy' (91.67%), 1 'Hold' (8.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Fennec Pharmaceuticals Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 15, 2024Chase KnickerbockerCraig-Hallum$17.00$7.34131.61%183.81%
May 15, 2024Raghuram SelvarajuH.C. Wainwright$15.00$7.03113.37%150.42%
Apr 04, 2024Raghuram SelvarajuH.C. Wainwright$18.00$10.7767.13%200.50%
Mar 19, 2024Chase KnickerbockerCraig-Hallum$18.00$11.0163.49%200.50%
Nov 22, 2022Cantor Fitzgerald$12.00$9.1730.86%100.33%
Sep 26, 2022Wedbush$19.00$7.11167.23%217.20%

The latest Fennec Pharmaceuticals stock forecast, released on May 15, 2024 by Chase Knickerbocker from Craig-Hallum, set a price target of $17.00, which represents a 131.61% increase from the stock price at the time of the forecast ($7.34), and a 183.81% increase from FENC last price ($5.99).

Fennec Pharmaceuticals Price Target by Period

1M3M12M
# Anlaysts--4
Avg Price Target--$17.00
Last Closing Price$5.99$5.99$5.99
Upside/Downside-100.00%-100.00%183.81%

In the current month, the average price target of Fennec Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Fennec Pharmaceuticals's last price of $5.99. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
May 15, 2024Craig-HallumBuyBuyHold
May 15, 2024H.C. WainwrightBuyBuyHold
Apr 04, 2024H.C. WainwrightBuyBuyHold
Nov 22, 2022Cantor FitzgeraldOverweightUpgrade
Sep 26, 2022WedbushOutperformOutperformHold
Sep 07, 2022JonesTradingBuyInitialise
Sep 07, 2022OppenheimerOutperformInitialise
Sep 07, 2022Morgan StanleyEqual-WeightInitialise
Sep 07, 2022JefferiesBuyInitialise
Sep 07, 2022NeedhamBuyInitialise
Sep 07, 2022UBSBuyInitialise
Sep 07, 2022Credit SuisseOutperformInitialise
Sep 07, 2022Alliance Global PartnersBuyInitialise

Fennec Pharmaceuticals's last stock rating was published by Craig-Hallum on May 15, 2024. The company gave FENC a "Buy" rating, the same as its previous rate.

Fennec Pharmaceuticals Financial Forecast

Fennec Pharmaceuticals Revenue Forecast

Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Dec 21
Revenue----------------$10.00M$6.51M$3.33M$1.68M$1.53M-
Avg Forecast$21.03M$20.25M$18.69M$17.91M$15.77M$15.18M$14.01M$13.43M$12.51M$18.05M$9.59M$8.30M$8.01M$8.99M$11.05M$10.21M$8.66M$5.33M$3.72M$1.84M$893.80K$50.00M
High Forecast$23.95M$23.06M$21.29M$20.40M$17.96M$17.29M$15.96M$15.30M$14.25M$20.56M$10.92M$9.83M$10.26M$10.23M$11.05M$10.21M$9.87M$5.37M$4.24M$2.10M$1.02M$50.00M
Low Forecast$18.72M$18.03M$16.64M$15.95M$14.04M$13.52M$12.48M$11.96M$11.14M$16.08M$8.54M$6.77M$5.76M$8.00M$11.05M$10.21M$7.71M$5.29M$3.32M$1.64M$795.83K$50.00M
# Analysts1111111111123111311111
Surprise %----------------1.15%1.22%0.89%0.91%1.72%-

Fennec Pharmaceuticals's average Quarter revenue forecast for Mar 24 based on 1 analysts is $10.21M, with a low forecast of $10.21M, and a high forecast of $10.21M. FENC's average Quarter revenue forecast represents a 2.10% increase compared to the company's last Quarter revenue of $10.00M (Dec 23).

Fennec Pharmaceuticals EBITDA Forecast

Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Dec 21
# Analysts1111111111123111311111
EBITDA----------------$-1.87M$-915.00K$-4.55M$-5.16M$-6.05M$-4.36M
Avg Forecast$-2.45M$-2.36M$-2.18M$-2.08M$-1.83M$-1.77M$-1.63M$-1.56M$-1.46M$-2.10M$-1.12M$-965.45K$-932.39K$-1.05M$-1.29M$-1.19M$-1.01M$-620.02K$-433.29K$-214.54K$-104.00K$-6.01M
High Forecast$-2.18M$-2.10M$-1.94M$-1.86M$-1.63M$-1.57M$-1.45M$-1.39M$-1.30M$-1.87M$-993.23K$-787.35K$-670.54K$-930.88K$-1.29M$-1.19M$-897.67K$-615.41K$-385.80K$-191.02K$-92.60K$-6.01M
Low Forecast$-2.79M$-2.68M$-2.48M$-2.37M$-2.09M$-2.01M$-1.86M$-1.78M$-1.66M$-2.39M$-1.27M$-1.14M$-1.19M$-1.19M$-1.29M$-1.19M$-1.15M$-624.64K$-493.50K$-244.35K$-118.45K$-6.01M
Surprise %----------------1.85%1.48%10.50%24.06%58.19%0.73%

undefined analysts predict FENC's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Fennec Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.

Fennec Pharmaceuticals Net Income Forecast

Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Dec 21
# Analysts1111111111123111311111
Net Income----------------$-2.76M$-1.87M$-5.44M$-7.63M$-7.79M$-4.49M
Avg Forecast----$1.76M$1.70M$1.57M$1.51M$729.90K$6.11M$-1.55M$-2.55M$-3.22M$-2.46M$-684.27K$-1.57M$-492.68K$-3.28M$-4.29M$-5.53M$-7.25M$20.40M
High Forecast----$2.08M$2.01M$1.85M$1.78M$861.75K$7.22M$-1.33M$-2.16M$-1.46M$-2.11M$-586.77K$-1.35M$739.02K$-2.82M$-3.68M$-4.74M$-6.22M$20.40M
Low Forecast----$1.51M$1.46M$1.35M$1.29M$625.89K$5.24M$-1.83M$-2.95M$-4.97M$-2.91M$-807.88K$-1.86M$-2.46M$-3.88M$-5.06M$-6.53M$-8.56M$20.40M
Surprise %----------------5.59%0.57%1.27%1.38%1.07%-0.22%

Fennec Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. FENC's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Fennec Pharmaceuticals SG&A Forecast

Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Dec 21
# Analysts1111111111123111311111
SG&A----------------$11.14M$7.19M$7.83M$6.85M$7.47M$3.68M
Avg Forecast$391.47M$376.97M$347.98M$333.48M$293.48M$282.61M$260.87M$250.02M$232.89M$336.09M$178.46M$154.46M$149.17M$167.26M$205.63M$190.14M$161.29M$99.19M$69.32M$34.32M$16.64M$930.75M
High Forecast$445.87M$429.35M$396.33M$379.81M$334.26M$321.88M$297.12M$284.76M$265.25M$382.79M$203.26M$182.95M$191.06M$190.50M$205.63M$190.14M$183.70M$99.93M$78.95M$39.09M$18.95M$930.75M
Low Forecast$348.56M$335.65M$309.83M$296.92M$261.32M$251.64M$232.28M$222.61M$207.36M$299.25M$158.90M$125.96M$107.28M$148.93M$205.62M$190.13M$143.61M$98.45M$61.72M$30.56M$14.81M$930.75M
Surprise %----------------0.07%0.07%0.11%0.20%0.45%0.00%

Fennec Pharmaceuticals's average Quarter SG&A projection for Mar 24 is $190.14M, based on 1 Wall Street analysts, with a range of $190.13M to $190.14M. The forecast indicates a 1607.47% rise compared to FENC last annual SG&A of $11.14M (Dec 23).

Fennec Pharmaceuticals EPS Forecast

Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Dec 21
# Analysts1111111111123111311111
EPS----------------$-0.10$-0.07$-0.21$-0.29$-0.30$-0.17
Avg Forecast----$0.06$0.06$0.06$0.06$0.03$0.22$-0.06$-0.09$-0.12$-0.09$-0.03$-0.06$-0.02$-0.12$-0.16$-0.20$-0.27$0.75
High Forecast----$0.08$0.07$0.07$0.06$0.03$0.26$-0.05$-0.08$-0.05$-0.08$-0.02$-0.05$0.03$-0.10$-0.13$-0.17$-0.23$0.75
Low Forecast----$0.06$0.05$0.05$0.05$0.02$0.19$-0.07$-0.11$-0.18$-0.11$-0.03$-0.07$-0.09$-0.14$-0.18$-0.24$-0.31$0.75
Surprise %----------------5.56%0.59%1.34%1.44%1.13%-0.23%

According to undefined Wall Street analysts, Fennec Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to FENC previous annual EPS of $NaN (undefined).

Fennec Pharmaceuticals Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
KROSKeros Therapeutics$18.00$102.00466.67%Buy
MOLNMolecular Partners$5.25$29.00452.38%Buy
AVTEAerovate Therapeutics$2.56$13.00407.81%Hold
ANEBAnebulo Pharmaceuticals$1.31$6.00358.02%Buy
OLMAOlema Pharmaceuticals$6.14$27.00339.74%Buy
LRMRLarimar Therapeutics$4.32$17.00293.52%Buy
FENCFennec Pharmaceuticals$6.07$15.75159.47%Buy
EWTXEdgewise Therapeutics$30.17$46.2553.30%Buy
HRMYHarmony Biosciences$33.63$48.0042.73%Buy
IRONDisc Medicine$65.00$77.6719.49%Buy
JANXJanux Therapeutics$59.61$70.2517.85%Buy
IKNAIkena Oncology$1.62$1.33-17.90%Buy

FENC Forecast FAQ

Is Fennec Pharmaceuticals a good buy?

Yes, according to 12 Wall Street analysts, Fennec Pharmaceuticals (FENC) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 11 'Buy' recommendations, accounting for 91.67% of FENC's total ratings.

What is FENC's price target?

Fennec Pharmaceuticals (FENC) average price target is $15.75 with a range of $12 to $19, implying a 162.94% from its last price of $5.99. The data is based on 12 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Fennec Pharmaceuticals stock go up soon?

According to Wall Street analysts' prediction for FENC stock, the company can go up by 162.94% (from the last price of $5.99 to the average price target of $15.75), up by 217.20% based on the highest stock price target, and up by 100.33% based on the lowest stock price target.

Can Fennec Pharmaceuticals stock reach $9?

FENC's average twelve months analyst stock price target of $15.75 supports the claim that Fennec Pharmaceuticals can reach $9 in the near future.

What are Fennec Pharmaceuticals's analysts' financial forecasts?

Fennec Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $58.39M (high $66.51M, low $51.99M), average EBITDA is $-6.794M (high $-6.05M, low $-7.738M), average net income is $6.54M (high $7.72M, low $5.61M), average SG&A $1.09B (high $1.24B, low $967.84M), and average EPS is $0.239 (high $0.282, low $0.205). FENC's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $77.89M (high $88.71M, low $69.35M), average EBITDA is $-9.063M (high $-8.069M, low $-10.322M), average net income is $0 (high $0, low $0), average SG&A $1.45B (high $1.65B, low $1.29B), and average EPS is $0 (high $0, low $0).

Did the FENC's actual financial results beat the analysts' financial forecasts?

Based on Fennec Pharmaceuticals's last annual report (Dec 2023), the company's revenue was $21.64M, beating the average analysts forecast of $19.56M by 10.64%. Apple's EBITDA was $-13.005M, beating the average prediction of $-2.276M by 471.40%. The company's net income was $-16.339M, beating the average estimation of $-13.594M by 20.19%. Apple's SG&A was $33.31M, missing the average forecast of $364.13M by -90.85%. Lastly, the company's EPS was $-0.61, beating the average prediction of $-0.497 by 22.82%. In terms of the last quarterly report (Dec 2023), Fennec Pharmaceuticals's revenue was $10M, beating the average analysts' forecast of $8.66M by 15.46%. The company's EBITDA was $-1.868M, beating the average prediction of $-1.008M by 85.31%. Fennec Pharmaceuticals's net income was $-2.756M, beating the average estimation of $-493K by 459.42%. The company's SG&A was $11.14M, missing the average forecast of $161.29M by -93.10%. Lastly, the company's EPS was $-0.1, beating the average prediction of $-0.018 by 455.56%